![Quiver Logo](/static/img/logo-icon.png)
![TLSIW logo](https://quiver-logos.s3.us-east-2.amazonaws.com/tlsiw.png)
TriSalus Life Sciences, Inc. Warrant
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TLSIW Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of TLSIW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TLSIW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to TLSIW
Recent picks made for TLSIW stock on CNBC
ETFs with the largest estimated holdings in TLSIW
Flights by private jets registered to TLSIW
![Quiver Logo](/static/img/logo-icon.png)